Employees: 251
Size CellaVision (CEVI.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $477M, the 177th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 203.50 on 18 Nov 2026.
Performance Over six months the shares gained 63.6%, against -19.0% for the median peer and +2.8% for the Sweden market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +2.7%); the operating margin is 23.0% (peer median 2.7%).
Valuation It trades at 32.6× forward earnings against a peer median of 19.7× (2nd most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.1 points above its cost of capital (6.1% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 763M | SEK 759M | SEK 723M | SEK 677M | SEK 639M |
| Revenue growth | — | +5% | +7% | +6% | — |
| Gross profit | SEK 519M | SEK 495M | SEK 463M | SEK 440M | SEK 413M |
| EBITDA | SEK 222M | SEK 241M | SEK 219M | SEK 207M | SEK 202M |
| Net income | SEK 138M | SEK 153M | SEK 141M | SEK 130M | SEK 118M |
| Free cash flow | SEK 182M | SEK 182M | SEK 186M | SEK 165M | SEK 114M |
| Capital expenditure | SEK 86.2M | SEK 86.3M | SEK 77.7M | SEK 86.5M | SEK 69.4M |
| Total debt | SEK 49.8M | SEK 25.7M | SEK 26.8M | SEK 64.7M | SEK 102M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CEVI.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +24.2% | -7.1% | 2nd highest of 21 |
| 6-month return | +63.6% | -19.0% | highest of 21 |
| Distance from 52-week high | -1.7% | -43.4% | highest of 21 |
| Revenue growth (TTM) | +1.9% | +2.7% | 11th highest of 21 |
| Operating margin | 23.0% | 2.7% | 3rd highest of 21 |
| Forward P/E | 32.6× | 19.7× | 2nd most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 7.1% | 7.7% | 7th least demanding of 13 |
| Growth delivered (Del g) | +10.0% | -3.6% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -2.9 pp | +7.7 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | +12.1 pp | -1.9 pp | 2nd highest of 19 |
| EV / EBITDA | 21.1× | 9.6× | most expensive of 4 |
| Net debt / EBITDA | -0.8× | -1.5× | 2nd most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 32.6× | 7.1% | +10.0% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | n/a | 55.3% | -4.7% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | n/a | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 11.9× | -5.9% | +7.7% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 22.4× | 4.3% | +24.4% |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 6.9× | -6.5% | -4.3% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 24.5× | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 25.8× | n/a | n/a |
| MiMedx MDXG | United States | $464M | -16% | -23% | -8% | n/a | 10.9% | +11.0% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 19.4× | 4.5% | +5.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | 1% | n/a | 36.0% | -6.9% |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -1,178% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| Guangdong Shirongzhaoye 002016.SZ | China | $453M | -26% | -31% | 3% | n/a | 21.5% | -11.7% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $452M | -12% | 0% | 10% | n/a | -1.0% | -2.8% |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | n/a | 30.8% | -18.6% |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | n/a | n/a | n/a |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 13.2× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 57.3× | 0.4% | -13.2% |